SINGPAORE - Media OutReach - 23 September 2019 - The Hong Kong-based Asian Fund for Cancer Research (AFCR) last Thursday, September 19, introduced Bridging Research from Academia to Cancer Entrepreneurship. The program was inaugurated in Singapore as the first of what will be a series of BRACE Award Competitions throughout Asia. Conducted over the course of the day, the event culminated in the selection of the cancer research project presented by F. Joel Leong, M.D., Ph.D., chief development officer at A*STAR's Experimental Drug Discovery Centre, as its winner and the project presented by Volker Patzel, Ph.D., assistant professor at the National University of Singapore's Yong Loo Lin School of Medicine, as its runner-up.
BRACE Award Competitions aim to identify and catalyze early-stage cancer laboratory discoveries with viable clinical trial pathways. The first such event featured 20 individual research projects from institutions including the National University of Singapore, the National Cancer Centre Singapore, three A*STAR research entities, the Hong Kong University of Science and Technology and multiple young cancer technology companies.
Evaluating the presentations was a panel of world-class cancer research professionals, including AFCR scientific advisory board members. Its members were Ludwig Institute for Cancer Research's Webster Cavenee, Ph.D., Harvard Medical School's Raju Kucherlapati, Ph.D., former Avera Cancer Institute's Brian Leyland-Jones, M.D., Ph.D., Eight Roads Ventures' Will Liu, Ph.D., National Cancer Centre Singapore's Kanaga Sabapathy, Ph.D., University of Hong Kong's George Tsao, Ph.D., National Foundation for Cancer Research's (NFCR) Michael Wang, M.D., Ph.D., and MD Anderson Cancer Center's W.K. Alfred Yung, M.D.
Dr. Leong's winning project comprises ETC-159, a novel small molecule drug candidate for colorectal cancer and other solid tumours. Dr. Patzel's runner-up project represents a unique gene therapy delivery vector targeting hepatocellular carcinoma. The BRACE Award Competition's other three finalists were the cancer research projects presented by Duke-NUS Medical School Professor and Lion TCR Scientific Founder Antonio Bertoletti, M.D., Cancer Science Institute of Singapore Senior Research Scientist Bee Hui Liu, Ph.D., and A*STAR's Genome Institute of Singapore Principal Investigator Wai Leong Tam, Ph.D.
The awardees, along with those selected at future BRACE Award Competitions, will be introduced by AFCR to its funded scientists, scientific advisory board members and other affiliates pertinent to their research, including fellows of U.S.-based NFCR. In addition, start-up firms which license the projects or are formed to further develop them can in the future compete for multiyear recoverable translational research grants or equity investments.
"We are tremendously excited to have held so successful an inaugural BRACE Award Competition" said AFCR Chief Executive Officer Sujuan Ba, Ph.D., the organization's founder. "This new program aims to raise the profile of lab breakthroughs which can anchor future novel cancer therapies and other technologies."
"The BRACE Award Competition program will certainly help catalyze laboratory cancer research in the region," expressed AFCR Chairman of the Board Gary (Gee Nung) Wong, a partner of Hugill & Ip Solicitors, which, along with NFCR and Esco Ventures, sponsored last night's event.
About the Asian Fund for Cancer Research
The Asian Fund for Cancer Research (AFCR) is a non-profit organization committed to curing cancers that have significant impacts on Asian populations. Headquartered in Hong Kong, AFCR is uniquely positioned to implement in Asia the newest cancer research discoveries and technologies from around the world, investigate the distinct causes of cancer in Asian populations through innovative genetic and molecular research, and develop more effective therapies tailored to the region's cancer patients. For more information, visithttps://www.afcr.org.
About Hugill & Ip Solicitors
Hugill & Ip Solicitors is an independent law firm providing bespoke legal advice and exceptional client service to individuals, families, entrepreneurs and businesses, in Hong Kong and internationally. Hugill & Ip provides high quality legal services with integrity, professionalism and respect for clients and the community. For more information, visithttps://www.hugillandip.com.
© 2019 Media OutReach Limited. All Rights Reserved.
OPKO Health (Nasdaq: OPK) and Pfizer (NYSE: PFE) Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
**Disclaimer: Crown Equity Holdings Inc. has received $5,000.00 (five thousand dollars) in cash from Nass Valley Gateway Ltd. (CSE:NVG) (FSE:3NVN) for 30 days of advertisement services